Bedtime Dosing of Antihypertensives Can Reduce Cardiovascular Risks for CKD Patients

Taking at least one hypertensive medication at bedtime instead of upon waking can reduce the risk of cardiovascular events by as much as two thirds, reports Ramón C. Hermida and associates in the December Journal of the American Society of Nephrology (JASN). This simple and costless approach could lead to significant improvements in outcomes for patients with high blood pressure (BP) whether or not they have chronic kidney disease (CKD) and could change how nephrologists administer antihypertensive drugs for their patients.

Circadian rhythms and blood pressure dipping

There is a natural tendency for BP to drop during sleep. But people with high BP have a tendency to not experience this dip and may even have a rise in BP at night. These patients—non-dippers and reverse dippers—tend to be at a higher risk for experiencing cardiovascular events.

Chronotherapy—using the body’s internal clock (chronotherapy)—may reduce this risk. The findings were reported in recent articles published together in the Journal of the American Society of Nephrology (JASN).

“Circadian rhythms and blood pressure dipping are natural,” said Eric G. Neilson MD, editor-in-chief of JASN. “We are only beginning to understand how these rhythms may impact therapies.”

Circadian rhythms and blood pressure dipping are natural, but they can be impacted by therapies. The research suggests that therapies could be adjusted to take advantage of these rhythms.

Circadian rhythms and blood pressure dipping are natural, but they can be impacted by therapies. The research suggests that therapies could be adjusted to take advantage of these rhythms.

Circadian rhythms and blood pressure dipping are natural, but they can be impacted by therapies. The research suggests that therapies could be adjusted to take advantage of these rhythms.

Circadian rhythms and blood pressure dipping are natural, but they can be impacted by therapies. The research suggests that therapies could be adjusted to take advantage of these rhythms.

Circadian rhythms and blood pressure dipping are natural, but they can be impacted by therapies. The research suggests that therapies could be adjusted to take advantage of these rhythms.
**APOL1 Gene Variants**

Continued from page 1

cent African descent. The APOL1 gene creates a protein that is a component of HDL, or good cholesterol. The protein circulates on HDL3 complexes, the densest HDL fraction, and is expressed in multiple tissue types. Researchers have wondered how variants in the APOL1 gene contribute to kidney disease and why certain variants are so common in African Americans.

Individuals inherit two copies of the APOL1 gene—one from each parent. It turns out that if they inherit one copy of an APOL1 gene variant, they are protected from the parasite Trypanosoma brucei rhodesiense that causes African sleeping sickness, a disease transmitted by the tse-tse fly. For this reason, these variants have been preserved through evolution and are common in individuals with African ancestry. Unfortunately, when both copies of the APOL1 gene contain a variant, a person has an increased risk of developing kidney failure.

**New insights on APOL1**

In the latest *JASN* studies, researchers investigated how common APOL1 gene variants are in individuals with and without kidney disease, examined whether African Americans with the variants need dialysis at a younger age than those without the variants, and analyzed individuals’ kidney tissues to see how the protein created by the APOL1 gene affects kidney health.

To determine how common APOL1 gene variants are, Ali Gharavi, MD, of Columbia University College of Physicians and Surgeons, and his colleagues looked for the variants in 74 healthy African Americans and African Americans with various common kidney disorders: 44 with focal segmental glomerulosclerosis (FSGS, which is characterized by scarring of the kidneys), 21 with HIV-associated nephropathy (HIVAN, a secondary form of FSGS linked with HIV infection), and 32 with IgA nephropathy (which occurs when antibodies build up in the kidneys). The researchers found that variants in the APOL1 gene often occurred in individuals with FSGS and HIVAN but not in those with IgA nephropathy. “This study confirms that genetic variation in the APOL1 gene is a major risk factor for two forms of kidney disease and that the risk imparted is significant enough that APOL1 testing may be used to determine people’s risk for kidney failure,” Gharavi said.

Delving deeper into the links between APOL1 gene variants and FSGS and HIVAN, Jeffrey Kopp, MD, of the National Institutes of Health, and his team studied 271 African American cases of FSGS and HIVAN, 168 European American cases, and 939 healthy individuals. African Americans with variants in both copies of the APOL1 gene had a significantly increased risk of developing FSGS and HIVAN. APOL1 variants conferred 17-fold higher odds for FSGS and 29-fold higher odds for HIVAN. Among those with either FSGS or HIVAN, having two APOL1 risk alleles could be responsible for 67 percent of cases.

Among the general population, two APOL1 risk alleles may account for 18 percent and 35 percent of FSGS and HIVAN, respectively. Approximately 13 percent of African Americans (more than 3.5 million individuals) carry two APOL1 gene variants, and these individuals have a 4 percent risk during their lifetime of developing FSGS; those with untreated HIV have a 50 percent risk during their lifetime of developing HIVAN. “We also found that APOL1-associated FSGS tended to arise at an earlier age and to progress to kidney failure more rapidly than non-APOL1-associated FSGS,” Kopp said.

Other researchers looked to see if APOL1 gene variants confer risks for other types of kidney disease among 2867 African Americans. Nondiabetics with two APOL1 gene variants had a fourfold increased risk of developing chronic kidney disease over nondiabetics without the gene variants, according to findings of Martin Pollak, MD, of Beth Israel Deaconess Medical Center, and his colleagues. African Americans with zero or one APOL1 risk allele, and African Americans with two risk alleles had microalbuminuria rates of 2.3 percent, 6.0 percent, and 16.5 percent, respectively. Rates of GFR < 60 mL/min/1.73 m² were 1.5 percent, 1.7 percent, and 6.7 percent for these same groups. APOL1 genotype was not associ-
Clinical impact

The proteins created by the APOL1 gene variants explain the difference between the high rate of kidney disease in African Americans compared with European Americans,” Pollak said.

Pollak also collaborated with Ravi Thadani, MD, of Massachusetts General Hospital, and others to examine whether African Americans with APOL1 gene variants need dialysis to treat kidney failure at a younger age than those without the variants. Among 407 African Americans with kidney failure, individuals with two gene variants initiated chronic hemodialysis at an average age of 49.0 years, compared with 55.9 years for those with one gene variant and 61.8 years for those with no variants. “We may be able to predict when blacks with kidney disease will experience kidney failure well before it occurs,” said Thadani. These results suggest that patients with two variants may benefit from early therapies to protect their kidneys.

While these association studies all provide new and valuable information, questions still remain regarding how the proteins created by the APOL1 gene and its variants affect kidney health. To investigate, John Sedor, MD, of Case Western Reserve University, and his collaborators examined individuals’ kidney tissues and found that the protein created by the APOL1 gene resides in different regions of the kidney in patients with FSGS or HIVAN compared to individuals without kidney disease. APOL1 in the normal human kidney was localized to the podocyte, a cell type implicated in the pathogenesis of FSGS and HIVAN, as well as in proximal tubular epithelial cells and the endothelium of small renal arteries. In FSGS and HIVAN samples, APOL1 staining was diminished in the podocytes and proximal tubules while it was preserved in the endothelium of small renal arteries. It was also present in the vessel walls of the small renal arteries.

“Our research shows that APOL1 variants explain the difference between the high rate of kidney disease in African Americans and what specific steps individuals with the variants should take to safeguard the health of their kidneys.

The APOL1 kidney disease connection comes at a time of rapid progress in the genome-wide identification of risk loci that interact with each other and with environmental triggers and cofactors in determining kidney function in health and disease, and we all look forward to continued progress,” Skorecki said.

More research is needed to understand how APOL1 variants contribute to kidney disease and what specific steps individuals with the variants should take to safeguard the health of their kidneys.

“The APOL1 kidney disease connection comes at a time of rapid progress in the genome-wide identification of risk loci that interact with each other and with environmental triggers and cofactors in determining kidney function in health and disease, and we all look forward to continued progress,” Skorecki said.

The link between APOL1 gene variants and kidney disease in African Americans has been one of the more exciting research developments at the intersection of nephrology, population genetics, and evolutionary medicine in recent years, said Karl Skorecki, MD, director of nephrology and molecular medicine at the Technion Faculty of Medicine in Israel. “These new JASN studies bring these insights closer to the benefit of the individual patient by providing genetic epidemiologic parameters that will be needed in establishing guidelines for personalized risk and preventive intervention assessments based on APOL1 genotype,” he said.
Bedtime Dosing of Antihypertensives

Continued from page 1

circadian rhythm patterns to increase the efficacy of medications—i.e., being studied in a wide variety of diseases, including cancer, asthma, and arthritis. The cardioprotective effects of using chronotherapy to administer hypertensive medications at bedtime have been previously studied (Smolensky MH, et al. Blood Press Monit 2010; 15:173–180), but this was the first study to confirm the effect by using ambulatory blood pressure (AMBP) monitoring data.

“A large number of published prospective trials have reported clinically meaningful morning-evening, treatment-time differences in BP-lowering efficacy, duration of action, safety profile, and/or effects on the circadian BP pattern for different classes of hypertension medications,” Hermida said. The group previously reported that urinary albumin excretion was significantly reduced with the nighttime dosing of valsartan (Hermida RC, et al. Hypertension 2005; 46:960–968). Hermida called the finding “just one single example of too many similar findings for many hypertension medications.”

The MAPEC [Ambulatory Blood Pressure Monitoring and Cardiovascular Events] study, from which the current report in JASN was derived, “was designed to test exactly what we documented, and the results were expected,” Hermida said. “We were, however, surprised by the extent of the differences between groups.” The MAPEC study appeared in Chronobiology International in 2010.

“There has been a longitudinal concern about the lack of good nocturnal BP control in many patients with hypertension, including those with CKD, said Frank C. Brosius III, MD, chief of the division of nephrology at the University of Michigan and a special

Ambulatory blood pressure monitoring

Between 2000 and 2007, Hermida and his colleagues at the University of Vigo in Spain conducted a prospective open-label investigation with 661 patients randomly assigned to either take at least one antihypertensive medication at bedtime or take all their medications upon waking in the morning. At the beginning of the study period, both groups had similar renal and cardiovascular profiles.

Patients were monitored for two endpoints: 1) total cardiovascular events, including death, myocardial infarction (MI), angina pectoris, revascularization, heart failure, artery occlusion, and stroke, and 2) major cardiovascular events (cardiovascular death, MI, and stroke). This focus is important because “there have been no relatively large studies of the effect of such therapy on ‘hard’ cardiovascular end-points in CKD patients,” Brosius said.

The investigators were able to capture the real-time data needed to confirm the beneficial effects of bedtime dosing through the use of AMBP monitoring. Each patient wore a portable BP monitor for 48 hours before each follow-up visit, and BP measurements were recorded every 20 minutes during the day and early every 30 minutes during the night. Asleep and awake periods were verified with actigraphy to ensure accurate data capture. Although previous research has confirmed the importance of nighttime BP in predicting the risk of cardiovascular events, this was based only on the AMBP data obtained at the beginning of the study, with no AMBP data captured in the follow-up period.
Significant cardiovascular outcomes

After a median follow-up time of 5.4 years, patients in the bedtime dosing arm had experienced 35 cardiovascular events compared with 104 events in the morning dosing arm. Major cardiovascular events affected 9 of the patients in the bedtime dosing arm, compared with 26 events in the morning dosing arm. In addition to the primary endpoints of cardiovascular outcomes, patients taking at least one medication at bedtime also experienced better outcomes in reducing albumin excretion.

“These treatment-time–dependent effects on sleep-time BP control were strongly associated with lower risk of [cardiovascular disease] events,” the group determined. “Indeed, the progressive reduction in the asleep BP mean from baseline was the most significant predictor of event-free survival.

“The results indicate that [cardiovascular disease] event rates in patients with hypertension can be reduced by more than 50 percent with a zero-cost strategy of administering blood pressure-lowering medications at bedtime rather than in the morning,” Hermida said, adding that “differences between treatment-time groups were greater than anticipated due to some extent to the very minor number of events in the group of patients who were ingesting not just one but all medications at bedtime.”

Brosius found the results “striking and provocative, but cautioned that “since this is a single-center study and because of the degree of risk reduction, these results need to be confirmed in a larger, multiinstitutional randomized controlled trial.”

Hermida concurred: “The current report in JASN is just a subgroup analysis from the much larger MAPEC study. Fully comparable results, also derived from our much larger study, have been previously reported for subgroups of patients with diabetes (Hermida RC, et al. Diabetes Care 2011; 34:1270–1276), resistant hypertension (Hermida RC, et al. Chronobiol Int 2010; 27:1629–1651), or for the general hypertension population (Hermida RC, et al. J Am Coll Cardiol 2011; 58:1165–1173). These findings, however, will need further corroboration by larger studies.”

Hermida and his colleagues are currently coordinating a multicenter prospective trial with the participation of primary care centers from Northwest Spain to corroborate the findings. Termed the Hygia Project, the new trial will test hypotheses similar to those from the MAPEC study. So far the team has recruited over 9000 patients who are being followed by repeated 48-hour ABPM monitoring.

And despite the single-center scale of the current study in JASN, Brosius said that “since there is no known adverse consequence from nocturnal dosing of most antihypertensives I, for one, will consider more regularly prescribing these medications at bedtime, as well as in the morning.”

---

2011 Corporate Supporters

The ASN Corporate Support Program recognizes supporters year round for their generous contributions to the Society. Through this program, supporters help ASN lead the fight against kidney disease. ASN gratefully acknowledges the following companies for their contributions in 2011.
Renal Denervation for Control of Treatment-resistant Hypertension

Even Lower Isn’t For Diabetic Dialysis Patients, Low A1C is Good, but Even Lower Isn’t

Two new studies show that when it comes to hemoglobin A1c in dialysis patients, Goldilocks had it right—the best level is not too high, but not too low either. Both studies show that the lowest mortality occurred in patients with intermediate levels, ranging between 6.5 percent and 9 percent, and that dropping below that was associated with worse patient outcomes.

The guidelines for control of blood sugar in the Kidney Disease Outcomes Quality Initiative (KDOQI), dating to 2007, state that the target A1c level for people with diabetes should be less than 7 percent, irrespective of the presence or absence of chronic kidney disease.” However, according to Kamyar Kalantar-Zadeh, MD, professor of medicine and pediatrics and epidemiology at the UCLA David Geffen School of Medicine in Los Angeles, “There is no consistent evidence to support these targets for dialysis patients.” Kalantar-Zadeh was lead investigator on one of the new studies.

Previous large observational studies have come to different conclusions about the effect of A1c on mortality in dialysis patients. But these studies have generally been relatively short-term, he said. To determine the long-term effect of A1c, he and his colleagues examined outcomes in over 54,000 dialysis patients with diabetes over a seven-year period.

They found that mortality from all causes followed a U-shaped curve in relation to time-averaged A1c. The lowest rate of mortality occurred when A1c was between 7 percent and 8 percent. In line with previous studies, it rose sharply above that, with the hazard ratio rising to approximately 1.4 when A1c was in the 9 percent to 10 percent range. Surprisingly, though, the hazard ratio also rose when A1c was below 7 percent, increasing gradually when the level was between 6 percent and 7 percent, and then steeply as the level dropped below 6 percent. The risk of death at an A1c level of 5 percent was higher than at levels between 9 percent and 10 percent.

The same U-shaped curve was found for mortality from cardiovascular events, again with a nadir at A1c levels between 7 percent and 8 percent, with approximately similar magnitudes of risk on either side. Kalantar-Zadeh also analyzed mortality as a function of glucose levels directly, using random glucose samples in over 50,000 patients. The lowest mortality was seen in patients with time-averaged glucose in the 150–200 mg/dl range, with the risk increasing from either more, or less, glucose.

A second study, part of the Dialysis Outcomes and Practice Pattern Study (DOPPS), reached similar conclusions, according to investigator Fritz Port, MD, of Arbor Research in Ann Arbor, Michigan. In this prospective study of over 6000 dialysis patients with diabetes from 12 countries, after fully adjusting for a range of variables affecting mortality, the lowest mortality occurred in patients with A1c levels between 7 percent and 7.9 percent.

“The desirable range for diabetic dialysis patients is 7 percent to 9 percent,” Port said, “which is higher than the guidelines for the general diabetes population.” To improve patient survival, he said, diabetes medications could be reduced in patients with low blood sugar, a step that may be particularly important for patients with poor nutritional status.

“I think the take-home message is that the target may need to be reconsidered in diabetic dialysis patients,” Kalantar-Zadeh said, suggesting 6.5 percent to 8 percent as the appropriate range. Importantly, “the target has a lower threshold, not just an upper threshold.”

“It also has practical implications,” he said. “Patients do not need to be pressured all the time to achieve the same very low levels as in the general diabetes population. We may be satisfied with patients reaching the middle range.”

The reason that dialysis patients differ from other diabetic patients is not clear. One reason may be that dialysis patients have adapted to moderately high glucose, reaching a new normal, and so for them, lowering glucose below 6.5 percent or 7 percent is not beneficial.

While the findings of the two studies coincide, neither was a randomized trial comparing different target glucose levels. Thus, Kalantar-Zadeh said, there is a need for controlled trials to further confirm these findings.

The findings were presented at Kidney Week 2011.
A Lifetime of Proving Them Wrong: Robert Langer and the Development of “Bioartificial” Tissues

"They said it wouldn't work" has been a galvanizing challenge to Robert Langer, Sc.D., throughout his long and astonishingly productive career. Langer has been a pioneer in the creation of biomaterials for drug delivery, and more recently in laying the foundations for the development of engineered tissues, including those in development for treatment of renal disease. He delivered a state of the art plenary lecture here during Kidney Week in Philadelphia.

As a young man wanting to put his chemical engineering skills to some creative use, Langer approached Judah Folkman, a cancer researcher whom Langer had heard “sometimes hired unusual people.” Folkman was in the early days of seeking angiogenesis inhibitors as antitumor agents, and it fell to Langer to prospect for candidates in bovine cartilage, which is largely devoid of blood vessels. This, he said, led to long hours scraping the thigh bones of “most of the cows in the Northeast.”

Most significantly, this early work led him to make fundamental advances in polymer chemistry, designing polymers that could hold, and equally importantly slowly release, large molecules such as proteins. The chemistry establishment was skeptical of such a feat was possible. But he showed them wrong, creating polymers with high “tortuosity,” full of large pores that twisted throughout the structure. He published his initial landmark results in Nature, in 1976. The polymer was used to deliver candidate angiogenesis inhibitors for in vivo testing. That research led, three decades later, to Avastin for colorectal cancer.

That research led, three decades later, to angiogenesis inhibitors for in vivo testing. The polymer was used to deliver candidate angiogenesis inhibitors for in vivo testing. That research led, three decades later, to Avastin for colorectal cancer. Langer has devoted much of the art plenary lecture here during Kidney Week to his professional life in biomaterials for drug delivery, and more recently to an important effort he has spearheaded—building new kidney replacement systems.

The artificial kidney has been a long-sought, largely unattainable desire. The development of bioartificial kidney systems has a history beginning with Robert Glidden, a medical student at the University of Chicago who, in 1935, experimented with maintaining mince of animal kidneys in a closed system. Glidden found that perfusing the system with blood and then dialyzing the effluent produced urine. Glidden’s work laid the foundation for subsequent efforts to build artificial kidneys.

As a young man, Langer was captivated by the idea of a wearable kidney. He took a journey to the University of Michigan, a cutting-edge center for biomaterials research. Several researchers, including David Humes, MD, professor of internal medicine at the University of Michigan. In an interview with Kidney News, Langer described the development of a bioartificial kidney as “a new frontier.” Of the two central functions of the kidney, dialysis handles only one: filtration clearance. The other, which combines reabsorption with metabolic and synthetic capacities, is the role of the tubule, and it is replacing the tubule to which Humes has devoted many years of research.

“The field has advanced considerably,” Humes said. He spearheaded a successful phase II trial of an extracorporeal tubule cell cartridge for acute kidney disease, which cut mortality in half. But as other treatment strategies emerged, that application has become less important.

For the last several years, Humes has been developing “a compact, wearable device” that can be combined with peritoneal dialysis for end stage renal disease. The tubule cells in the device are bathed in peritoneal fluid to keep them healthy. “The concept of a fully functional, bioartificial, wearable kidney has now been conceptually formulated,” he said, “and a proof of concept has been made in a large animal model.” Miniaturization would allow the device to be implanted, but that remains “a number of years away.”

Still further away is the replication of the tissue architecture of the kidney itself, which integrates the clearance and reabsorption functions in a compact and efficient package. “That is the ultimate challenge,” he said, but one that is orders of magnitude harder than sculpting cartilage. Tubules have at least 10 segments with different functions: cells of the right type might be injected under computer control into a dissolvable matrix, Hume speculated, but would still need the appropriate vasculature and innervation. “That would be a tour de force.”

“The extracorporeal systems are here already,” he said, but remain in the lab, awaiting both further development and a commercial rationale that would support that development. “It is difficult to add any costly component to the system in ESRD, unless there is a cost savings that can be identified.” Decreasing a patient’s dependence on dialysis centers might provide the financial savings that would justify the cost of the system, he suggested.

Available Now

BRCU Online

Nearly 65 hours of slides and audio help you prepare For board certification and recertification

ASN’s Board Review Course & Update (BRCU) is the most comprehensive review for the nephrology board examinations.

BRCU Online offers:

• World-renowned faculty
• Complete curriculum
• Convenience of distance learning

www.asn-online.org/learningcenter
Podocyturia in Pregnancy Gets New Look

By Tracy Hampton

Hypertension or preeclampsia during pregnancy, while often asymptomatic, can threaten the health of women and their babies. Two Mayo Clinic studies presented at the ASN’s Kidney Week 2011 provide new information related to these conditions.

Vesna Garovic, MD, and her team examined the potential of a test done mid-pregnancy to predict which women will later develop preeclampsia, a late-pregnancy disorder that is characterized by hypertension and proteinuria that affects 3 percent to 5 percent of pregnancies. Left untreated or without careful monitoring, preeclampsia can lead to serious—even fatal—complications for a pregnant woman and her baby.

The researchers previously showed that podocyturia, the shedding of five kidney cells called podocytes, is present at delivery in patients with preeclampsia. In this study, they tested whether podocyturia is predictive of later development of preeclampsia, and whether it can differentiate among normotensive pregnancies, gestational hypertension, and preeclampsia. For the analysis, urine sediments are cultured for 24 hours to select for viable cells, and podocytes are then identified on the basis of podocin staining.

Among a group of 315 patients in the study, 15 developed preeclampsia and 15 developed gestational hypertension (but not preeclampsia) during pregnancy. All of the patients who developed preeclampsia tested positive for podocyturia in mid-pregnancy (prior to 210 days gestation). None of the study participants with only hypertension tested positive, and none of 44 women with normal pregnancies tested positive.

The test is highly accurate for predicting preeclampsia, which could alert clinicians to take steps to safeguard against the condition in their patients. The test could also differentiate between later development of gestational hypertension and preeclampsia. The high accuracy of this test further supports the role of podocyte loss in the mechanism of proteinuria in preeclampsia.

“Preeclampsia is well recognized as an endothelial cell disease; however, the precise mechanism of proteinuria has remained somewhat elusive,” said Michelle Hladunewich, MD, who was not involved with the research and is a clinical investigator in the divisions of nephrology, critical care, and obstetric medicine at Sunnybrook Health Sciences Center in Toronto. “Although widespread feasibility of the measurement of podocytes in the urine as a predictive marker for preeclampsia is likely limited, these novel insights into the pathophysiology of preeclampsia particularly as it relates to the cross talk between the endothelial cell and the podocyte are most interesting.”

Garovic also led another study that looked at the long-term health effects of hypertensive disorders during pregnancy. Her team identified all female residents of Rochester, Minn., and the surrounding townships in Olmsted County who delivered between 1976 and 1982. The women were categorized into two groups: those with hypertensive disorders during pregnancy and those without. The investigators followed the women after they reached 40 years of age to monitor their heart and kidney health.

A total of 6051 mothers delivered between 1976 and 1982, and 607 women had hypertensive pregnancy disorders at the time while 5444 did not. Follow-up after age 40 years was available for 465 (77 percent) cases and 3898 (72 percent) controls. After the women reached age 40, women who had hypertensive disorders during pregnancy were much more likely to experience hypertension, kidney dysfunction (proteinuria, chronic kidney disease, or end stage renal disease), and strokes than women who did not have hypertensive disorders during pregnancy (51 percent vs. 31 percent, 14 percent vs. 10 percent, and 8 percent vs. 4 percent, respectively).

“Studies of the associations of hypertensive pregnancy disorders with maternal risks for future cardiovascular disease could lead to new guidelines for screening and treatment of women at risk, with the ultimate goal of improving cardiovascular health in women,” Garovic said.

Fish Oil Cuts Loss of Graft Patency and Cardiovascular Events in Dialysis Patients

For patients with a hemodialysis graft, daily fish oil substantially reduces the frequency of developing stenosis, thrombosis, and cardiovascular complications. “This message from a large, randomized, placebo-controlled study presented at Kidney Week in November.

The results, according to lead investigator Charmaine Lok, MD, should prompt a fresh look at grafts and the potential of fish oil to improve patient outcomes in hemodialysis. Lok is associate professor of medicine at University of British Columbia, and medical director of the Hemodialysis Vascular Access Program at Toronto General Hospital.

Each type of hemodialysis access has its problems. Lok noted, with stenosis and thrombosis being the major problems with grafts. These problems have led to an increasing use of fistulas, but over the past decade, she said, it has become apparent that fistulas often fail, with estimates of failure rates ranging up to 60 percent.

The reasons for stenosis are not entirely clear, although multiple factors are likely involved, including trauma during surgery or during treatment. “It has been known for a long time that fish oil has beneficial anti-inflammatory properties,” Lok said, dating back to studies on Eskimo populations in Greenland, who have very low levels of cardiovascular disease.

Fish oil reduces endothelial dysfunction through several mechanisms, including reduction of inflammatory cytokines and inhibition of endothelin-1, which constricts blood vessels.

That led Lok to wonder if fish oil might also have a beneficial effect on blood vessels elsewhere in the body, including the vessels supplying the graft. A small study in 2002 suggested that might be the case, with treatment increasing graft patency fivefold versus placebo over 12 months.

For her study, Lok recruited patients with patent grafts a week after their surgery. Patients were randomized to receive placebo or fish oil at 4 grams per day for 12 months, during which they underwent biweekly follow-up visits to assess patency, and every 3 months to monitor lipid profiles, blood pressure, and cardiovascular events. The study was conducted at 12 sites in Canada and 3 sites in the United States.

The primary outcome was the proportion of patients with loss of patency within 12 months, as evidenced by having either a thrombosis or need for an intervention to maintain graft patency. “Either you have an event, or you don’t—that’s the most conservative endpoint,” she said. Prespecified secondary outcomes included the individual rates of thrombosis or need for intervention to restore patency, the time to thrombosis, and changes in blood pressure, lipid profile, and cardiovascular medications.

The study was designed to enroll 232 patients, but, Lok said, “we had a very hard time recruiting patients, because of the push for fistulas” within the last several years. In the end, she enrolled 201 patients, of whom 101 received fish oil. Patients had a mean age of 62 years, and were well matched except for a higher proportion of congestive heart failure in the fish oil group. That imbalance increased the challenge for active treatment to show benefit, she said, but also meant that a positive result might be more meaningful.

On the primary outcome measure, 48 percent of patients in the fish oil group, and 62 percent in the placebo group, had loss of patency. The difference was just shy of statistical significance, with a p value of 0.06.

Fish oil was superior on almost all the secondary outcome measures. The rate of thrombosis or need for intervention per 1000 days was 3.43 for fish oil, versus 5.95 for placebo (p <0.001). The median time to thrombosis was twice as long for patients on fish oil, and the rate of thrombosis was half, with 1.7 events per 1000 days for patients on fish oil, versus 3.4 for placebo (p <0.001). The rate of any cardiovascular event in patients on fish oil was less than half that of patients on placebo.

Blood pressure was reduced, as were medications. Lipid profiles were not different between the groups, perhaps, Lok said, because baseline levels were relatively low, making it difficult for treatment to have much effect.

The failure of treatment to significantly affect the primary endpoint, while providing clear superiority on many clinically important secondary ones, suggests to Lok that, in hindsight, an alternative primary endpoint may have been better. Patients who have an event may continue to use their graft, she noted, and so at that point, the more important clinical question is, “For the duration of the access, how many of these events are you going to have? From a patient and healthcare payer perspective, that is probably the most important endpoint. An intervention is extremely expensive, and inconvenient and painful for the patient.”

“There is a role for grafts in hemodialysis? There absolutely is,” Lok said. “After a decade of promoting fistulas, we are finding out there is a high failure rate. For patients who are not eligible for fistulas, grafts are a good alternative.”

“We were very excited about the cardiovascular outcomes,” Lok said, and her group is currently pursuing a larger study in dialysis patients to formally study the effect of fish oil on these events.

Kidney Week 2011
Diabetes Trials Take Kidneys into Consideration

Type 1 diabetes’ risk of developing impaired glomerular filtration decreased 50 percent when they were given intensive diabetes therapy, according to late-breaking clinical trial results presented at Kidney Week. Other late-breaking findings pointed to the promising clinical potential of sitagliptin for patients with type 2 diabetes who have moderate or severe chronic renal insufficiency (CRI).

Diabetes and kidney dysfunction often go hand-in-hand, so researchers know that it’s important to study the effects of diabetes drugs on the kidneys and to examine the safety of these drugs in patients who already have kidney disease.

In the first study, the Diabetes Control and Complications Trial (DCCT), Ian de Boer, MD, of the University of Washington, and his team looked to see if intensive diabetes therapy aimed at reducing blood sugar as close to the normal range as possible might protect type 1 diabetes’ kidney function.

“Persons with type 1 diabetes are at high risk of developing kidney disease, but no interventions are proven to prevent the development of impaired glomerular filtration rate, or GFR, in this population,” de Boer said.

The researchers randomly assigned 1441 individuals with type 1 diabetes to intensive diabetes therapy or to conventional diabetes therapy, aimed at preventing symptoms of high blood sugar. Patients were treated for an average of 6.5 years. Subsequently, 1375 participants were followed in the observational Epidemiology of Diabetest Interventions and Complications Study (EDIC).

Over an average of 22 years in DCCT/EDIC, intensive therapy was more effective at preserving long-term kidney function in study participants. A total of 24 participants assigned to intensive therapy and 46 assigned to conventional therapy developed impaired GFR, meaning that intensive diabetes therapy reduced patients’ risk by 50 percent. Of those with impaired kidney function, 8 assigned to intensive therapy and 16 assigned to conventional therapy developed kidney failure.

Compared with conventional therapy, intensive therapy reduced mean estimated GFR by 1.7 mL/min/1.73 m² during the DCCT but slowed the rate of GFR loss and increased the mean estimated GFR by 2.5 mL/min/1.73 m² during EDIC. So small short-term reductions in GFR within the normal range were followed by long-term GFR preservation. The beneficial effect of intensive therapy on impaired GFR was fully explained by lower hemoglobin A1c and lower albumin excretion rate.

“This important study shows that loss of kidney function is potentially preventable in people with type 1 diabetes and adds to our understanding of the importance of controlling blood sugar in this population,” said Marcello Tonelli, MD, who moderated the late-breaking oral abstract session. Tonelli is president of the Canadian Society of Nephrology and a founding member of the Alberta Kidney Disease Network.

Another study compared the efficacy and safety of blood-sugar-lowering drugs in patients with type 2 diabetes and chronic renal insufficiency (CRI).

Previous research indicates that two of these drugs, sitagliptin and glipizide, may not cause considerable kidney damage. The agents act on different targets but generate the same result—they boost the effects of insulin, which lowers blood sugar levels.

Juan Arjona Ferreira, MD, of MSD Corp. and his colleagues conducted a 54-week study to compare the efficacy and safety of sitagliptin and glipizide in patients with type 2 diabetes and moderate or severe CRI who were not on dialysis. The researchers randomized 426 patients to receive sitagliptin or glipizide.

The sitagliptin dose was 50 mg once daily for patients with moderate CRI and 25 mg once daily for patients with severe CRI. The dose was adjusted downward (from 50 to 25 mg once daily) for patients whose renal status changed from moderate to severe based on confirmed estimated GFR values. The glipizide dose was 2.5 mg once daily and could be titrated up to 10 mg twice daily. The primary efficacy endpoint was the mean change from baseline in A1C. The primary safety endpoint was the incidence of adverse events of symptomatic hypoglycemia, or dangerously low blood sugar levels.

At the end of the study, blood glucose levels dropped to a similar extent in patients in both groups. Patients receiving sitagliptin were less likely to experience hypoglycemia than patients receiving glipizide (6.2 percent vs. 17.0 percent). Also, patients who took sitagliptin tended to lose a small amount of weight, while most patients who took glipizide experienced a slight weight gain.

Join or renew
ASN membership online at www.asn-online.org/membership
**Turnabout Is Fair Play**

DaVita, the second largest provider of dialysis services in North America, is acquiring its first operations in Europe—in Germany.

What makes the deal particularly interesting is that Germany is the headquarters of the largest provider of dialysis services and products worldwide. Fresenius Medical Care is based in Bad Homburg, Germany. Fresenius North America is well established, but DaVita is just starting to get its feet wet across the oceans. DaVita already has expanded into Asia, providing dialysis services in Singapore and in Bangalore, India, and has an agreement to develop and operate dialysis clinics in Malaysia, according to the company web site.

“The time is right for DaVita to extend to Europe and Asia,” said DaVita chairman and CEO Kent Thiry. “Our patient-centric care model is being well received on both continents.” Denver-based DaVita is taking it slowly. The Denver Post reports that Thiry is cautiously optimistic—and candid—about the new expansion plans. “If I was smarter, we would have started this several years ago,” Thiry said. “Over the next 10 years, we intend to deliberately and thoroughly create a material global presence. . . . We’ll make some mistakes, since we’re new at it.”

---

**Soliris**

(Soliris®)

- Soliris is the first and only approved therapy for pediatric and adult patients with atypical Hemolytic Uremic Syndrome (aHUS)\(^1\,\,^2\)
- In aHUS, uncontrolled terminal complement activation results in thrombotic microangiopathy (TMA)\(^1\)
- Soliris inhibits uncontrolled complement activation and complement-mediated TMA in patients with aHUS\(^1\)

For more information, contact your Alexion representative or call 1-888-SOLIRIS (1-888-765-4747) today.
Acquisition Particulars

DaVita dialysis services is now reaping the benefits of its acquisition of rival firm, DSI Renal.

In the third quarter of 2011, DaVita reported a higher profit because of new revenue streams from its acquisition. According to Associated Press (AP), for the quarter that ended September 30, DaVita earned $135.3 million, an improvement over the $119.4 million for the same time period last year. The company’s revenue increased 9.5 percent to $1.8 billion for the period.

At the close of the quarter, the company had 1777 outpatient dialysis centers serving roughly 138,000 patients. The company acquired 113 new centers with its purchase of DSI Renal and divested 28 centers to complete the acquisition.

The company reiterated its expected 2011 income guidance of between $1.1 billion and $1.2 billion.

On the downside of business, however, the company noted that it expected to get subpoenaed by federal investigators looking into payments made to the company for dialysis services in New York State’s Medicaid program. This would add to subpoenas in recent years from U.S. Justice Department staff in Missouri and Colorado and Health and Human Services officials in Texas. The New York investigation will examine payments for infusion drugs for dialysis that are covered by the state’s Medicaid system, used by the poor and uninsured.

In a smaller bit of acquisition news, there is currently debate in Vermont, which is also playing out around the country, as established dialysis clinics in smaller markets sell off to larger companies that could run them more efficiently. In Vermont, the sale of five dialysis clinics to Fresenius may bring in an estimated $26 million to the state’s largest hospital.

Fletcher Allen Health Care operates the clinics at a loss. Officials there say that the sale of the clinics to Fresenius Medical Care will let the Fletcher Allen hospital continue to offer a necessary service for patients in a more cost-effective way, according to Vermont Digger, a journalism web site.

Representatives of the Vermont Federation of Nurses and Health Professionals are critical of the proposed saleoff. They say that the sale could worsen quality of care for patients and decrease wages for hospital workers who may staff those clinics.

Fresenius is applying for approval from the state to purchase the clinics. Vermont Digger reported that the state nurses’ union is concerned about public input in the state approval process, because an act passed in the most recent legislative session eliminated the Public Oversight Commission.

In 2010, Fletcher Allen publicly announced it would sell five clinics to Bio-Medical Applications of New Hampshire, Inc., which is a subsidiary of Fresenius Medical Care North America.

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTIONS

See full prescribing information for complete boxed warning

Life-threatening and fatal meningococcal infections have occurred in patients treated with Soliris. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early.

- Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccination in patients with complement deficiencies.
- Immunize patients with a meningococcal vaccine at least 2 weeks prior to administering the first dose of Soliris, unless the risks of delaying Soliris therapy outweigh the risk of developing a meningococcal infection. (See Serious Meningococcal Infections for additional guidance on the management of the risk of meningococcal infection.)
- Monitor patients for early signs of meningococcal infections, and evaluate immediately if infection is suspected.

Soliris is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS). Under the Soliris REMS prescribers must enroll in the program. Enrollment in the Soliris REMS program and additional information are available by telephone: 1-888-SOLIRIS (1-888-765-4747).

Indications and usage

Soliris is indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to inhibit complement-mediated thrombotic microangiopathy.

The effectiveness of Soliris in aHUS is based on the effects on thrombotic microangiopathy (TMA) and renal function. Prospective clinical trials in additional patients are ongoing to confirm the benefit of Soliris in patients with aHUS.

Limitation of Use

Soliris is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).

Adverse reactions

The most frequently reported adverse reactions in the PNH randomized trial (≥10% overall and combined per patient incidence) are: hypertension, upper respiratory tract infection, diarrhea, headache, anemia, vomiting, nausea, urinary tract infection, and leukopenia.

Please see brief summary of Prescribing Information, including Boxed WARNING, on the following page.

ASN Partners to Fund Research for Rare Nephrotic Syndrome Disease

The American Society of Nephrology (ASN) has partnered with The Halpin Foundation since 2003 to fund an annual research grant for new investigators focusing on membranous nephropathy (MN). “When we began our collaboration, we had very little funding in membranous research,” says Joan Halpin, Ph.D., President of The Halpin Foundation. “The Halpin Foundation. The partnership with ASN highlighted the disease and encouraged young researchers to pursue MN research.”

The Halpin Foundation strongly supports collaboration in research in autism research and affordable access to treatments. It was one of the primary sponsors of this year’s Membranous Nephropathy International Conference in Bergamo, Italy, at the Mario Negri Institute (having also sponsored the conference in 2006). Mrs. Halpin represents the foundation on the steering committee of the Nephrotic Syndrome Study Network (Neptune).

The Halpin Foundation-ASN Research Grant has sponsored a number of exciting projects, including, most recently, “Direction of anti-phospholipid A2 antibodies in MN: a cohort study of 361 patients,” by Suzanne D. Kandari, M.D., Ph.D., at the University of Miami School of Medicine. This project, which looks at the role of anti-phospholipid antibodies in MN, was a key project in the 2011 grant cycle. The Halpin Foundation has also added $10,000 to the grant to provide travel funds for the majority of immunemediated membranous disease.

In 2012, ASN will begin a new partnership with The NephroCare Foundation-ASN Research Grant, also for new investigators, will focus funding on focal segmental glomerulosclerosis (FSGS) or nephrotic syndrome. NephCare is pleased to partner with ASN and strongly supports the goals of its Career Development Grants program for New Investigators.

“With this partnership, we increase our funding and focus on glomerular disease and hopefully will attract more young researchers to this area of investigation,” Ms. Halpin adds.

The NephCare Foundation is the only organization exclusively to support research seeking the cause of FSGS and nephrotic syndrome, improving treatment, and finding a cure.

ASN provides more than $3 million each year for research grants. In addition to The Halpin Foundation-ASN Research Grant and The NephCare Foundation-ASN Research Grant, the Society offers research grants for new investigators, bridge funding for established investigators, research fellowships, and stipends for medical student research. “ASN is committed to providing a robust research grants program to ensure the success of the next generation of nephrologists and kidney researchers,” asserts ASN President Ronald J. Falk, MD, FASN.

The deadline to apply for The Halpin Foundation-ASN Research Grant and The NephCare Foundation-ASN Research Grant is Friday, January 27, 2012. For more information on the grants program, please visit www.asn-online.org/grants_and_funding. 

---

New Funding Opportunity for Fellows

Starting in July 2012, the ASN Research Fellowship Program will foster the training of fellows high in kidney disease-related research and contribute to the understanding of kidney biology and disease. Each ASN Research Fellowship provides $50,000 per year for up to two years.

“Together, we must support a robust cadre of young investigators who will bring enthusiasm, intelligence, and ingenuity to our scientific challenges. The future of nephrology depends on constant innovation, on helping the next generation succeed, and on our collective effort to better understand kidney disease,” says ASN Past President Joseph V. Bonventre, MD, FASN.

The deadline to apply for ASN Research Fellowships is Friday, January 27, 2012, at 4 p.m. EST. For more details or to apply, visit the ASN Research Fellowship Program website at http://www.asn-online.org/grants_and_funding/research-fellowships-details.aspx.
Member Benefits

Education
ASN provides member discounts for a variety of exceptional educational activities:
- **ASN Highlights 2012** summarize, critique, and integrate key Kidney Week 2011 presentations in powerful two-day courses (presented in four locations across the United States).
- **Board Review Course and Update 2012** prepares nephrologists for the ABIM initial certification and maintenance of certification examinations and provides a comprehensive update for the practicing nephrologist.
- **ASN Kidney Week 2012** remains the world’s premier gathering of kidney professionals presenting advances in treatment, research, and education.

Abstract Submission allows members to submit and sponsor abstracts for oral and poster presentation at ASN Kidney Week.

ASN In-Training Examination for Nephrology Fellows helps identify gaps in training and is similar in design to the ABIM certifying examination.

Online Geriatric Nephrology Curriculum provides essential education in geriatric nephrology.

Grants & Funding
ASN funds more than $3 million annually for research and travel grants.

Membership Services
ASN supports several initiatives to enhance members’ careers:
- **Membership Directory**
  Access ASN member contact information through a searchable online directory.
- **ASN Committees and Advisory Groups**
  Volunteer to serve on an ASN committee and help guide the future direction of the society.
- **ASN Career Center**
  Advertise jobs, review candidates, post resumes, apply for positions, and reach employers and recruiters—all through one website.
- **Fellows of the American Society of Nephrology (FASN)**
  Achieve FASN status and have your outstanding credentials, achievements, and scholarship recognized.

Policy and Public Affairs
Stay informed about how current and future legislation affects nephrology and improve treatment, research, and education by volunteering to help ASN advocate on behalf of members and their patients.

Publications and Communications
Receive all ASN publications and communications in print and online:
- **Journal of the American Society of Nephrology (JASN)**
  The leading kidney journal in the world.
- **Clinical Journal of the American Society of Nephrology (CJASN)**
  The primary resource for cutting edge clinical research in nephrology.
- **Nephrology Self-Assessment Program (NephSAP)**
  An essential tool for earning continuing medical education credits and maintenance of certification points.
- **ASN Kidney News**
  A news magazine offering exceptional coverage of current issues of interest to kidney professionals.
- **ASN Kidney News Podcasts**
  A bi-monthly audio program providing in-depth discussions of topics that interest and challenge the global kidney community.
- **ASN Kidney Daily**
  A daily email collating kidney-related news from medical journals, newspapers, and other media.
- **ASN Social Media**
  Connect, engage, and stay informed through the ASN Facebook, Twitter, and YouTube sites.

Member Categories

**Active Member ($315)**
An individual who holds an MD, a PhD, or the equivalent, resides in North or Central America, and fulfills at least one of the following criteria:
- Completion of research or clinical training in nephrology.
- Specialized training in nephrology during residency or other relevant postgraduate education.
- Publication of at least one peer-reviewed paper in nephrology.
- Experience as a specialist in kidney disease and related conditions.

**Corresponding Member ($315)**
An individual who meets the criteria for active membership but resides outside North or Central America.

**Affiliate Member ($315)**
An individual in nephrology or allied fields who is not eligible for Active or Corresponding membership.

**Medical Student/Resident (FREE)**
VERIFICATION REQUIRED
Enrolled in an accredited Internal Medicine, Pathology, or Pediatric residency, MS4 status, or enrolled in Medical-Scientist Training Program.

**Women in Nephrology (WIN) ($75)**
WIN provides access to senior women in the field of nephrology who mentor more junior physicians and scientists. Please note that WIN membership is separate from ASN membership.

**Retired Member (FREE)**
A senior member retired from clinical, research, and teaching activities who wants to receive print and online subscriptions to ASN publications.

Only **Active, Corresponding, and Affiliate** members may use the online membership system. To enroll in the Retired, Fellow-in-Training and Medical Student/Resident categories, please download and print the membership form from the ASN website or contact ASN Membership Director Pamela Beard at 202-640-4668 or pbeard@asn-online.org.

Join or Renew
ASN membership online at www.asn-online.org/membership/
Medicare Finalizes Changes to ESRD Quality Program, Releases Accountable Care Organization Rules

By Rachel Shaffer

The Centers for Medicare and Medicaid Services (CMS) last month released its long-awaited rule finalizing changes to the End-Stage Renal Disease Program (ESRD) payment system and the Quality Incentive Program (QIP). The final rule outlined modifications to the ESRD prospective payment system (PPS) for 2012, and it cemented adjustments—as well as major additions—to the QIP program across 2013 and 2014.

The ESRD PPS/QIP final rule came on the heels of another piece of CMS regulation that has been much anticipated by the medical community: the Accountable Care Organization (ACO) final rule, released in late October. The ASN Public Policy Board and the ASN ACO Task Force began analyzing the final rules upon their release to identify their implications for the ESRD program and the practice of nephrology.

ESRD, PPS, and QIP final rule

Taking effect January 1, 2012, the ESRD QIP is the first-ever mandatory payment-for-performance (also known as value-based purchasing) program in the Medicare system. Having finalized the parameters for the first year of the QIP in December 2010, in this final rule the CMS finalized a key component of the second year of the program, 2013, and broad changes to 2014, the third QIP year (Table 1).

Perhaps the most controversial change to the QIP in 2013 is the decision by the CMS to eliminate the quality measure for anemia management at the low end of the hemoglobin spectrum: percentage of Medicare patients at a facility whose hemoglobin levels were greater than 12 g/dL. Many in the nephrology community, including the ASN, raised concerns that the absence of any minimal safeguards for low hemoglobin levels could be problematic for patients, potentially leading to compromised quality of life and functional status or even necessitating otherwise avoidable blood transfusions, and they stated these concerns in comments on the proposed rule. The Congressional Kidney Caucus recently expressed similar concerns about retiring the measure in a letter to the CMS on October 13, 2011.

The CMS acknowledged these concerns in the final rule but cited its own recent National Coverage Decision for ESAs for Treatment of Anemia in Adults, which concluded that the CMS could not identify a low hemoglobin target level that is safe for all patients, as part of its rationale for eliminating the measure. The CMS also noted that it conversed with the U.S. Food and Drug Administration, which agreed that retiring the measure is consistent with its recently revised label for ESAs. Consequently, in 2013 the QIP will comprise just two, equally weighted, quality measures:

- Percentage of Medicare patients with a hemoglobin level >12.0 g/dL (national performance rate = 14 percent of patients)
- Percentage of Medicare patients with a urea reduction ratio (URR) >65 percent (national performance rate = 97 percent of patients)

The CMS will also ratchet up the standards that facilities must achieve to avoid a payment reduction. In 2013, facilities must score the full possible 30 points—a change from QIP year 2012, when scoring 26 points would prevent any payment reductions. The performance year (the year from which data will be analyzed to develop scores in 2013) is 2011.

In 2014, the CMS will retain the 2012 measures and add four new measures, bringing the total to six. The one clinical measure added is a combined measure: vascular access type, examining 1) catheter reduction and 2) arteriovenous fistula use. Three of the four new measures, listed below, are reporting-only (yes/no) measures:

- Report dialysis infections to the Centers for Disease Control and Prevention NHSN Dialysis event reporting system.
- Administer ICH Consumer Assessment of Health Policy Study.
- Monitor mineral metabolism (phosphorus and calcium levels).

In the proposed rule, the CMS suggested, but did not finalize, the following three measures for 2014:

Control and Prevention NHSN Dialysis event reporting system.

- Kt/V (which would have replaced the URR measure of dialysis adequacy): The CMS noted its intention to finalize the Kt/V measures in the future once it could “ensure the validity and consistency” of Kt/V data.
- Standardized Hospitalization Ratio-Admissions (SHR): The CMS did not finalize the SHR measures because of concerns articulated by the ASN in its comment letter that the measure might not reflect hospitalizations related to ESRD care and could increase the potential for cherry-picking.
- Vascular access infections (VAI): The CMS concluded that the claims-based data the measure would be based on are not detailed enough to accurately reflect care.

The CMS finalized the bulk of its proposal to adopt a new performance scoring methodology for 2014. The performance of facilities will be determined by the higher of an “Achievement” score (worth up to 10 points) or an “Improve” score (worth up to 9 points) for clinical measures, with a slightly different approach for the vascular access type. The benchmark to achieve full points in measures on both scales is set as the 90th percentile of all performers nationwide (a change from the proposed rule, in which the CMS proposed to set the benchmark as the mean of the top decile of all performers). More detailed information about the scoring is available on the ASN’s public policy webpage (http://www.asn-online.org/policy_and_public_affairs/esrd-bun-dling.aspx).

Accountable Care Organization final rule

The 609-page ACO final rule creates more generous opportunities for providers to share in savings, relaxes the EHR meaningful use criteria, and reduces the number of quality measures that ACOs must achieve from 65 to 33. And these are just some of the final rule’s many changes to the ACO program compared with the original proposed rule (Table 2).

The CMS received more than 1300 comments on the proposed rule—including from ASN—most of which criticized the proposed program as being too burdensome, being too prescriptive, and offering few financial benefits for participating providers. The CMS responded to many of these concerns in the final rule.

The ASN ACO Task Force is in the

Table 1. Evolution of the Medicare ESRD program, 2012–2014

<table>
<thead>
<tr>
<th>Consequence Year</th>
<th>Performance Year</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quality measures and performance standards</td>
<td>• Hemodialysis adequacy (URR)</td>
<td>• Hemodialysis adequacy (URR)</td>
<td>• Hemoglobin &gt; 12 g/dL: 26% of patients</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Hemoglobin &lt; 10 g/dL: 2% of patients</td>
<td>• Hemoglobin &gt; 12 g/dL: 14% of patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Hemoglobin &gt; 12 g/dL: 14% of patients</td>
<td>• Hemoglobin &gt; 12 g/dL</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Abbreviations: CAHPS = Consumer Assessment of Health Policy Study; ICD = International Classification of Diseases; URR = urea reduction ratio.*
ACOs and Nephrology

By Caroline Jennette

Often compared to the health maintenance organizations (HMOs) of the past, accountable care organizations (ACOs) have taken the spotlight as a new model of health care delivery and payment under the Affordable Care Act. Mark McClellan, MD, PhD, former administrator of the Centers for Medicare & Medicaid Services and current director of the Engberg Center for Health Care Reform, spoke about ACOs at the 2011 Kidney Week and later at the American Society of Nephrology (ASN) policy forum at Kidney Week 2011. McClellan sees ACOs as an opportunity for health care providers to take a more systematic approach to care and to work together to improve outcomes for patients.

Table 2. Key features of the ACO final rule

<table>
<thead>
<tr>
<th>Feature</th>
<th>Detail</th>
</tr>
</thead>
<tbody>
<tr>
<td>Providers eligible</td>
<td>• Physician practices</td>
</tr>
<tr>
<td>to start an ACO</td>
<td>• Network of physicians</td>
</tr>
<tr>
<td></td>
<td>• Physician/hospital joint venture</td>
</tr>
<tr>
<td></td>
<td>• Hospitals employing physicians</td>
</tr>
<tr>
<td></td>
<td>• Critical Access Hospitals</td>
</tr>
<tr>
<td></td>
<td>• Federally Qualified Health Centers (added in final rule)</td>
</tr>
<tr>
<td></td>
<td>• Rural Health Clinics (added in final rule)</td>
</tr>
<tr>
<td>Patient attribution</td>
<td>Patients preliminarily prospectively attributed to an ACO for savings</td>
</tr>
<tr>
<td>methodoloogy</td>
<td>that is based on prior healthcare utilization data, with final</td>
</tr>
<tr>
<td></td>
<td>reconciliation at the end of a performance year based on which the</td>
</tr>
<tr>
<td></td>
<td>ACO actually served</td>
</tr>
<tr>
<td>Quality measures</td>
<td>65 quality measures in five domains reduced to 33 measures in four</td>
</tr>
<tr>
<td></td>
<td>domains</td>
</tr>
<tr>
<td>Evidence-based</td>
<td>ACOs are required to develop, implement,</td>
</tr>
<tr>
<td>medicine</td>
<td>and document use of evidence-based medicine or clinical practice</td>
</tr>
<tr>
<td></td>
<td>guidelines and processes</td>
</tr>
<tr>
<td></td>
<td>ACOs to develop, implement, and document use of evidence-based</td>
</tr>
<tr>
<td></td>
<td>medicine or clinical practice guidelines and processes</td>
</tr>
<tr>
<td>Patient choice</td>
<td>ACOs must notify patients that they are receiving care from providers</td>
</tr>
<tr>
<td></td>
<td>that participate in an ACO; however, patients are free to seek care</td>
</tr>
<tr>
<td></td>
<td>outside the ACO from other providers</td>
</tr>
<tr>
<td></td>
<td>ACOs must notify patients that they are receiving care from providers</td>
</tr>
<tr>
<td></td>
<td>that participate in an ACO; however, patients are free to seek care</td>
</tr>
<tr>
<td></td>
<td>outside the ACO from other providers</td>
</tr>
<tr>
<td>Electronic health</td>
<td>Eliminated proposed requirement that at least 50 percent of</td>
</tr>
<tr>
<td>records</td>
<td>participating physicians be certified “meaningful users” of EHR</td>
</tr>
<tr>
<td></td>
<td>ACOs are required to develop, implement,</td>
</tr>
<tr>
<td></td>
<td>and document use of evidence-based medicine or clinical practice</td>
</tr>
<tr>
<td></td>
<td>guidelines and processes</td>
</tr>
<tr>
<td></td>
<td>ACOs to develop, implement, and document use of evidence-based</td>
</tr>
<tr>
<td></td>
<td>medicine or clinical practice guidelines and processes</td>
</tr>
<tr>
<td>Shared savings</td>
<td>ACOs can share cost savings (at either 50 percent or 60 percent) from</td>
</tr>
<tr>
<td></td>
<td>the first dollar saved, rather than after reaching a 2 percent</td>
</tr>
<tr>
<td></td>
<td>threshold as proposed</td>
</tr>
</tbody>
</table>

Abbreviations: ACO = Accountable Care Organization; EHR = electronic health record.

The Mayo Clinic’s “Re-Engineering Dialysis” or RED program uses the principals of accountable care—aligning financial incentives, collaboration between providers, flexibility in care models, and partnering with patients, said Amy Williams, MD, associate professor of medicine at Mayo Clinic. The nephrology team at Mayo is working to better understand patient needs as a way to increase patient capacity to deal with their illness and thus decrease the burden of disease.

ACOs are high-quality (and low-cost) coordinated care with payments based on the value of services versus quantity. While fee for service (FFS) payment systems can be used for ACOs, McClellan speculates that bundled payments for services will grow, especially with continuing bipartisan political support. He envisions a potential for savings through quality improvement with payments moving away from FFS and toward case coordination and care management fees driven by performance measures.

Physicians have an important role in helping design better systems of health care delivery, McClellan said. He called on nephrologists to continue to provide input, and ultimately be “bellwethers” for reforming care in other parts of the healthcare system.

The Mayo Clinic’s “Re-Engineering Dialysis” or RED program uses the principals of accountable care—aligning financial incentives, collaboration between providers, flexibility in care models, and partnering with patients, said Amy Williams, MD, associate professor of medicine at Mayo Clinic. The nephrology team at Mayo is working to better understand patient needs as a way to increase patient capacity to deal with their illness and thus decrease the burden of disease.

Mark Pauly, PhD, a health economist and professor of health care management at the University of Pennsylvania, took a more pessimistic view on ACOs. He argued that health care costs are being driven by an aging population, improvements in technology, and rising wages for health care providers, not by the costs of delivering FFS care. Pauly said that successful coordinated care models (e.g., Kaiser Permanente) have been very hard to reproduce. He forecasts that ACOs will eventually convert to de facto capitation. He suggests that instead of removing FFS as the dominant system of payment, it may be possible to take a market-based approach by titrating FFS payments down until payments are truly aligned with the appropriate number of services.

Williams and Pauly spoke at the public policy forum at Kidney Week 2011.
NEW

JASN Mobile App

• Titles, Abstracts, and Full-text
• Links to supplemental data and related articles
• Graphics optimized to the highest supported resolution
• Caching of content for easy offline access to articles
• Bookmarking of favorites to My List
• ASN Calendar RSS feed
• Access to social media

Download the free JASN App at the Apple Store today!

Now available as a free download from the App Store.
Chicago, IL
March 17 – 18, 2012

Berlin, Germany
January 21 – 22, 2012

Dallas, TX
March 3 – 4, 2012

For the Kidney Week sessions you missed
For a synopsis of key topics in nephrology
For critiques and perspectives by leaders in the field
Earn CME credits
- Acute Kidney Injury
- Clinical Nephrology
- End-Stage Renal Disease
- Hypertension
- Kidney Transplantation
- Parenchymal Disorders

Cartagena, Colombia
April 18, 2012

Washington, DC
April 28 – 29, 2012

New York, NY
May 5 – 6, 2012

For a synopsis of key topics in nephrology
For critiques and perspectives by leaders in the field
Earn CME credits
- Acute Kidney Injury
- Clinical Nephrology
- End-Stage Renal Disease
- Hypertension
- Kidney Transplantation
- Parenchymal Disorders

The perfect complement to Kidney Week

ASN
LEADING THE FIGHT AGAINST KIDNEY DISEASE
Worsening chronic kidney disease (CKD) is linked to increasing coronary artery calcification (CAC) independently of traditional risk factors, reports a study in the American Journal of Kidney Diseases.

The study included a multiethnic sample of CKD patients from the Chronic Renal Insufficiency Cohort Study. All patients underwent coronary artery calcification (CAC) measurement on the basis of the Agatston CAC score. The association between estimated GFR (eGFR) and CAC was assessed.

The results showed a strong graded association between decreased kidney function and increased CAC. On unadjusted analysis, the odds ratio for having a higher CAC score increased from 1.68 at an eGFR of 50 to 59 mL/min/1.73 m² to 2.82 at an eGFR less than 30 mL/min/1.73 m². The association was somewhat weakened on multivariate analysis but was still significant; odd ratio 1.53 at an eGFR less than 30 mL/min/1.73 m². The association was independent of traditional risk factors and albuminuria.

Coronary artery calcification is a risk factor for fatal and nonfatal cardiovascular events, but its significance in the CKD population is unclear. This cross-sectional study of CKD patients finds that lower levels of kidney function are independently associated with higher CAC.

The results may have important implications for the care of patients with CKD, especially in light of recent guidelines calling for vascular/valvular calcification to be considered in individualized treatment. The ongoing study will collect data on cardiovascular events in patients with CKD. [Budoff MJ, et al. Relationship of estimated GFR and coronary artery calcification in the CRIC (Chronic Renal Insufficiency Cohort) study. Am J Kidney Dis 2011; 58:519–526.]

Why Do Young Transplant Patients Have Poor Outcomes after Transfer to Adult Care?

The increased rate of adverse outcomes in adolescent and young adult patients transferred from pediatric to adult care appears to reflect factors other than the transfer itself, suggests a report in BMC Nephrology. The researchers analyzed graft survival in three Canadian cohorts of young patients undergoing kidney transplantation at affiliated pediatric and adult hospitals from 1990 through 2009. Transplantation was performed by the same surgeons even though the two sites were geographically separate. Children are transferred from the pediatric to the adult medical team at about age 18.

Outcomes for 49 pediatric patients undergoing transplantation at a pediatric hospital were compared with outcomes for two cohorts undergoing transplantation at the adult hospital: 48 young adults 18 to less than 25; and 124 adults 25 to 35. Death-censored graft survival was assessed by a multivariate Cox model.

There was no significant difference in graft survival between the pediatric and young adult cohorts. However, survival was significantly better in the adult cohort. The three cohorts had similar rates of admitted nonadherence. Transfer from the pediatric to the adult center occurred within a relatively narrow age window of 16.6 to 20.9 years. However, the time since transplantation varied substantially: range 0.9 to 11.0 years. Graft function at the time of transfer was also variable. Six of 18 pediatric patients had a serum creatinine greater than 180 μmol/L at transfer; all of these grafts eventually failed.

Addressing the concern that pediatric transplant patients transferred to adult centers are at increased risk for graft loss, the researchers write, [Khiwed IA, et al. Kidney transplantation in Canadian children: one year in the adult setting. Pediatr Nephrol 2008; 23:1783–92.] Transfer from pediatric to the adult center occurred within a relatively narrow age window of 16.6 to 20.9 years. However, the time since transplantation varied substantially: range 0.9 to 11.0 years. Graft function at the time of transfer was also variable. Six of 18 pediatric patients had a serum creatinine greater than 180 μmol/L at transfer; all of these grafts eventually failed.

How Often Should Diabetic Patients See Their Primary Care Doctor?

Making primary care visits every 2 weeks leads to faster achievement of glucose-, blood pressure- and cholesterol-targets in patients with diabetes, reports a study in the Archives of Internal Medicine.

The retrospective study included 26,496 patients with diabetes receiving primary care at two Boston hospitals between 2000 and 2009. The frequency of primary care encounters, assessed from notes in the medical records, was analyzed as a predictor of time to achievement of target levels of hemoglobin A1c (HbA1c), blood pressure, and LDL cholesterol (LDL-C).

Primary care visits every 1 to 2 weeks were associated with shorter times to reaching all three targets compared with visits every 3 to 6 weeks. For patients not receiving insulin, the HbA1c target of less than 7.0 percent was met at a median of 4.4 months with visits every 1 to 2 weeks compared with 24.9 months for visits every 3 to 6 weeks. For patients using insulin, the medians were 10.1 versus 52.8 months.

Shorter intervals were also associated with faster achievement of a blood pressure under 130/85 mm Hg (1.3 versus 13.9 months) and LDL-C less than 100 mg/dL (3.2 versus 32.0 months). On multivariate analysis, doubling the time between visits increased the time to reaching target HbA1c by 35 percent in patients not using insulin and by 17 percent in those using insulin. Doubling the time between visits also increased the time to lowering blood pressure by 87 percent and time to lowering LDL-C by 27 percent. In general, no further reduction in time to reaching targets was achieved at intervals of less than 2 weeks.

The results suggest that more frequent primary care visits may shorten the time to achieving key clinical targets for patients with diabetes. There is a strong dose-response effect of visit frequency on all three outcomes evaluated. The effect remains significant even after treatment intensification is accounted for. [Morison F, et al. Encounter frequency and glucose level, blood pressure, and cholesterol level control in patients with diabetes mellitus. Arch Intern Med 2011; 171:1542–1550.]

Dialysis Is Starting Earlier, Study Finds

From the late 1990s to the late 2000s, long-term dialysis was initiated an average of nearly 150 days earlier, according to a study in the Archives of Internal Medicine.

Trends in the timing of initiation of long-term dialysis were assessed by use of information from the U.S. Renal Data System end stage renal disease registry. Information on estimated GFR (eGFR) at the time of the first long-term dialysis treatment was modeled for patients who started dialysis in 1997 versus those who began dialysis in 2007. Data from an integrated health care system were used to assess the predialysis eGFR slope.

Dialysis was initiated a mean of 147 days earlier in 2007 than in 1997, after differences in patient characteristics were taken into account. The difference was fairly consistent across most patient subgroups but was largest for patients 75 or older: mean 233 days.

The mean eGFR before dialysis increased from 6.8 mL/min/1.73 m² for those starting dialysis in 1997 to 9.9 mL/min/1.73 m² for those starting dialysis in 2007. As reflected by the new study, there is a trend toward starting long-term dialysis at higher rates of eGFR. The results suggest that patients in the United States are starting dialysis about 5 months earlier on average, and nearly 8 months earlier for patients 75 or older. "In the absence of strong evidence to suggest that earlier initiation of long-term dialysis is beneficial, these findings call for careful evaluation of contemporary dialysis initiation practices in the United States," the researchers write. [O'Hare AM, et al. Trends in timing of initiation of chronic dialysis in the United States. Arch Intern Med 2011; 171:1663–1669.]

Journal View

As eGFR Goes Down, Coronary Artery Calcium Goes Up

Trends in the timing of initiation of long-term dialysis were assessed by use of information from the U.S. Renal Data System end stage renal disease registry. Information on estimated GFR (eGFR) at the time of the first long-term dialysis treatment was modeled for patients who started dialysis in 1997 versus those who began dialysis in 2007. Data from an integrated health care system were used to assess the predialysis eGFR slope.

Dialysis was initiated a mean of 147 days earlier in 2007 than in 1997, after differences in patient characteristics were taken into account. The difference was fairly consistent across most patient subgroups but was largest for patients 75 or older: mean 233 days.

The mean eGFR before dialysis increased from 6.8 mL/min/1.73 m² for those starting dialysis in 1997 to 9.9 mL/min/1.73 m² for those starting dialysis in 2007. As reflected by the new study, there is a trend toward starting long-term dialysis at higher rates of eGFR. The results suggest that patients in the United States are starting dialysis about 5 months earlier on average, and nearly 8 months earlier for patients 75 or older. "In the absence of strong evidence to suggest that earlier initiation of long-term dialysis is beneficial, these findings call for careful evaluation of contemporary dialysis initiation practices in the United States," the researchers write. [O'Hare AM, et al. Trends in timing of initiation of chronic dialysis in the United States. Arch Intern Med 2011; 171:1663–1669.]

Trial Questions the Benefits of Frequent Nocturnal Dialysis

Nocturnal home dialysis performed six nights weekly does not improve mortality or other outcomes compared with conventional hemodialysis three times weekly, concludes a trial in Kidney International.

In the Frequent Hemodialysis Network Nocturnal Trial, 87 patients were randomly assigned to undergo conventional hemodialysis performed three times weekly or nocturnal home dialysis performed six times weekly. Single-use high-flux dialyzers were used for all sessions.

The patients assigned to frequent nocturnal home dialysis had a mean dialysis weekly standard of 4.72 Kt/Vurea, compared with Kt/Vurea in the conventional dialysis group. The average number of weekly treatments was about 75 percent higher, and the average weekly treatment time was more than twice as high.

Nevertheless, there was no significant difference in either of two coprimary outcomes: death or left ventricular mass, measured by magnetic resonance imaging, or death or SF-36 RAND Physical Health Composite. Frequent nocturnal dialysis was associated with better control of hyperphosphatemia and hypertension, with a trend toward increased vascular access interventions. Cognitive function and hospitalization were similar between groups.

Previous small studies have suggested that more frequent hemodialysis sessions, performed in the patient’s home at night, might have clinical benefits. The new trial finds few significant differences in outcomes with frequent nocturnal home dialysis compared with conventional hemodialysis. The authors note some key limitations of their study, including small sample size and reduced adherence to prescribed dialysis in the group receiving frequent nocturnal dialysis. [Rocco MV, et al. The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial. Kidney Int 2011; 80:1080–1091.]
Survival Advantage of Black Dialysis Patients Limited to Older Adults

Compared to white patients, risk of death is lower for black dialysis patients over age 50 but higher for black patients in younger age groups, reports The Journal of the American Medical Association.

The researchers analyzed data on 1,330,007 patients with incident end-stage renal disease (ESRD) patients captured by the U.S. Renal Data System between 1995 and 2009. Multivariate age-stratified Cox proportional hazards and competing risk models were used to compare risk of death for black and white patients. Median potential follow-up was 6.7 years.

Overall mortality was lower in black patients than white patients: 57.1 percent versus 63.5 percent, adjusted hazard ratio (HR) 1.93. However, on age-stratified analysis treating kidney transplantation as a competing risk, mortality was higher for black patients than white patients: HR 1.12. At age 51 to 60 years, the pattern reversed, with mortality of 50.9 percent for black patients and 51.5 percent for white patients: HR 0.93. This difference remained significant at older ages, with adjusted HRs of 0.87 from age 61 to 70, 0.85 from age 71 to 80, and 0.87 at age 80 and older.

Studies have consistently reported longer survival for black dialysis patients, compared to their white counterparts. The new study suggests that this survival advantage is limited to patients older than 50; in younger age groups, survival is lower for black patients than white patients. More study is needed to explore the reasons for the higher risk of death among young black patients on dialysis. [Kucirka LM, et al. Association of race and age with survival among patients undergoing dialysis. JAMA 2011; 171: 620–626].

No Increase in Birth Defects with First-Trimester ACE Inhibitors

Exposure to angiotensin-converting enzyme (ACE) inhibitors during the first trimester of pregnancy does not increase the risk of congenital malformations, reports the British Medical Journal.

The researchers analyzed data on 465,744 mother–infant pairs in the Kaiser Permanente Northern California region between 1995 and 2008. Linked clinical and pharmacy data were used to evaluate the relationship between maternal ACE inhibitor use during the first trimester and the risk of congenital malformations in live-born offspring.

The rate of ACE inhibitor use by pregnant women dropped sharply from 0.9/1000 in the first trimester to only 0.1/1000 in the second or third trimester. The prevalence of treatment with other antihypertensive agents was 2.4/1000 and 26.5/1000, respectively.

Women who used ACE inhibitors during the first trimester had a 3.9 percent rate of congenital heart defects in their offspring compared with 1.6 percent for women without hypertension or antihypertensive medication use. No significant association existed after adjustment for age, ethnicity, parity, and obesity. The rate of congenital heart defects among infants born to mothers using other antihypertensive drugs was 2.6 percent—not significantly different from the 2.4 percent rate for women who had hypertension but did not take antihypertensive drugs.

The ACE inhibitors have well-recognized fetal toxic effects during the second or third trimester. Addressing concerns raised by recent studies, the new results show no significant increase in congenital malformations associated with first-trimester exposure to ACE inhibitors. Any apparent increase in risk likely reflects the effects of hypertension itself rather than of antihypertensive medications. [Li DK, et al. Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in live-born offspring: a retrospective cohort study. BMJ 2011; 343:d5931].

CJASN Introduces…

CJASN eJournalClub

eJC offers:

• Topics that will be innovative and controversial
• An interactive and timely journal club experience
• Promotion of discussion among nephrologists
• Stimulating interactions with authors

Visit http://ejc.cjasn.org today!
The more we think about it, talk about it, and feel about it, the more we can do about CKD.

COMMUNI•K — making connections that matter

Takeda and Affymax are teaming up with the renal community to target the relevant issues in patient care for chronic kidney disease (CKD). We want to listen to you, learn about your challenges, and leverage your wisdom to work toward developing smart solutions.

COMMUNI•K™
You talk. We listen. Patients win.